CARDIOKINE, INC. CLOSES $50 MILLION SERIES B FINANCING

Cardiokine, Inc., a specialty pharmaceutical company focused on the development of drugs for the treatment and prevention of heart failure and related cardiovascular and metabolic indications, announced today the closing of a $50 million Series B preferred share equity offering.
Yahoo News